Completed
OBSERVATIONAL
NCT04083820
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by their study doctor. The study will last for about 6 to 8 months. The participants will be asked to complete some questionnaires about their health and their diabetes treatment. Participants will complete these during their normally scheduled visits with their study doctor.
Interventions
Name:
semaglutide
Type:
DRUG
Description:
Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
Primary Outcomes
Measure:
Change in Glycated Haemoglobin A1c (HbA1c)
TimeFrame:
Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38)
Description:
Measured in % point
Measure:
Change in Glycated Haemoglobin A1c (HbA1c)
TimeFrame:
Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38)
Description:
Measured in mmol/mol
Trial Information
NCT ID
NCT04083820
Status
Completed
Study Type
OBSERVATIONAL
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025